Q-omics provides the consensus-scored RAD51B profile across patient tissues and cancer cell-line models. RAD51B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RAD51B is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, RAD51B RNA expression shows 20,419 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, HNSC, and ACC as cancer lineages where RAD51B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAD51B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAD51B survival associations across molecular data types. RAD51B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAD51B RNA expression–survival associations across cancer types. High RAD51B expression shows unfavorable associations in BLCA, ACC, LGG, UVM and KIRP, but favorable associations in ESCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for RAD51B RNA expression.
This table summarizes RAD51B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RAD51B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAD51B shows lower tumor expression in KICH and BRCA and higher tumor expression in HNSC, LIHC, COAD and BLCA. The HNSC box plot shows higher RAD51B RNA expression in tumor versus normal tissue (log2 FC = +0.451, t-test p < 0.001).
This table shows molecular features associated with RAD51B in patient tissues and cancer cell lines. In patient samples, RAD51B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAD51B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
